Cargando…

The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study

BACKGROUND: The challenge of drug resistance to carbapenems is of international concern with leading to increased hospital lengths of stay, costs, and mortality rates. How to get rid of the vicious cycle of drug resistance, new drugs, and re-resistance, and even the emergence of all-drug-resistant b...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Chuanwei, Xia, Zhongni, Li, Gonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863129/
https://www.ncbi.nlm.nih.gov/pubmed/31814745
http://dx.doi.org/10.2147/IDR.S229009
_version_ 1783471696314892288
author Xin, Chuanwei
Xia, Zhongni
Li, Gonghua
author_facet Xin, Chuanwei
Xia, Zhongni
Li, Gonghua
author_sort Xin, Chuanwei
collection PubMed
description BACKGROUND: The challenge of drug resistance to carbapenems is of international concern with leading to increased hospital lengths of stay, costs, and mortality rates. How to get rid of the vicious cycle of drug resistance, new drugs, and re-resistance, and even the emergence of all-drug-resistant bacteria that humans cannot cope with, are the major challenges we face. To date, data about pharmaceutical interventions on the use of carbapenems are currently limited. PATIENTS AND METHODS: A retrospective cohort study was conducted to compare pre- and post-intervention in Tongde Hospital of Zhejiang Province. Pharmaceutical interventions were performed in the post-intervention group, including real time monitoring of medication orders, educative group activities, and making interventions to physicians. Intervention acceptance and outcomes, including the length of hospital stay, readmission rates, 30-day mortality, and utilization of carbapenems, which was evaluated by the daily defined doses (DDDs), the days of therapy (DOTs), and the cost of carbapenems, were reviewed. RESULTS: During the study, 593 interventions were provided by clinical pharmacists with an average acceptance rate of 82.79%. Compared with the pre-intervention group, prescriptions of carbapenems for pathogen-directed therapy were improved significantly in the post-intervention group (59.27% vs 21.74%, p=0.022). The DDDs decreased from 281.96 to 174.28 and DOTs decreased from 9.19 to 5.18 after pharmaceutical intervention, and the pharmaceutical interventions had significantly lower mean total cost of carbapenems ($13,828.8 vs $8137.1, p=0.004) and length of hospital stay (9.3±1.5 vs 15.9±2.2, p=0.014). There was a significant reduction in 30-day mortality in the post-intervention group (9.46% vs 17.86%, p=0.013) while there were no differences found in the 30-day readmission (20.19% vs 20.66%, p=0.99). CONCLUSION: Implementation of pharmaceutical interventions in our hospital successfully improved the appropriateness of carbapenem prescribing overall, and reduced the DDDs, DOTs, length of hospital day, and cost of carbapenems.
format Online
Article
Text
id pubmed-6863129
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68631292019-12-06 The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study Xin, Chuanwei Xia, Zhongni Li, Gonghua Infect Drug Resist Original Research BACKGROUND: The challenge of drug resistance to carbapenems is of international concern with leading to increased hospital lengths of stay, costs, and mortality rates. How to get rid of the vicious cycle of drug resistance, new drugs, and re-resistance, and even the emergence of all-drug-resistant bacteria that humans cannot cope with, are the major challenges we face. To date, data about pharmaceutical interventions on the use of carbapenems are currently limited. PATIENTS AND METHODS: A retrospective cohort study was conducted to compare pre- and post-intervention in Tongde Hospital of Zhejiang Province. Pharmaceutical interventions were performed in the post-intervention group, including real time monitoring of medication orders, educative group activities, and making interventions to physicians. Intervention acceptance and outcomes, including the length of hospital stay, readmission rates, 30-day mortality, and utilization of carbapenems, which was evaluated by the daily defined doses (DDDs), the days of therapy (DOTs), and the cost of carbapenems, were reviewed. RESULTS: During the study, 593 interventions were provided by clinical pharmacists with an average acceptance rate of 82.79%. Compared with the pre-intervention group, prescriptions of carbapenems for pathogen-directed therapy were improved significantly in the post-intervention group (59.27% vs 21.74%, p=0.022). The DDDs decreased from 281.96 to 174.28 and DOTs decreased from 9.19 to 5.18 after pharmaceutical intervention, and the pharmaceutical interventions had significantly lower mean total cost of carbapenems ($13,828.8 vs $8137.1, p=0.004) and length of hospital stay (9.3±1.5 vs 15.9±2.2, p=0.014). There was a significant reduction in 30-day mortality in the post-intervention group (9.46% vs 17.86%, p=0.013) while there were no differences found in the 30-day readmission (20.19% vs 20.66%, p=0.99). CONCLUSION: Implementation of pharmaceutical interventions in our hospital successfully improved the appropriateness of carbapenem prescribing overall, and reduced the DDDs, DOTs, length of hospital day, and cost of carbapenems. Dove 2019-11-15 /pmc/articles/PMC6863129/ /pubmed/31814745 http://dx.doi.org/10.2147/IDR.S229009 Text en © 2019 Xin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xin, Chuanwei
Xia, Zhongni
Li, Gonghua
The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title_full The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title_fullStr The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title_full_unstemmed The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title_short The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre–Post Study
title_sort impact of pharmaceutical interventions on the use of carbapenems in a chinese hospital: a pre–post study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863129/
https://www.ncbi.nlm.nih.gov/pubmed/31814745
http://dx.doi.org/10.2147/IDR.S229009
work_keys_str_mv AT xinchuanwei theimpactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy
AT xiazhongni theimpactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy
AT ligonghua theimpactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy
AT xinchuanwei impactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy
AT xiazhongni impactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy
AT ligonghua impactofpharmaceuticalinterventionsontheuseofcarbapenemsinachinesehospitalaprepoststudy